Table 1.
Demographics and baseline characteristics.
| ITT population (n = 15) | |
|---|---|
| Age, yr, mean (SD) | 30.5 (9.0) |
| Male, n (%) | 13 (86.7) |
| Race, n (%) | |
| Caucasian | 15 (100) |
| FEV1, (L), mean (SD) | 3.8 (0.6) |
| % Predicted FEV1, mean (SD) | 86.5 (9.2) |
| Maximum % decrease in FEV1 postdose/pre-challenge at screening, mean (SD) | −26.5 (7.0) |
| Patients with allergic rhinitis, n (%) | 15 (100) |
| Concomitant medication during the double blind period, n (%) | |
| Montelukast sodium | 1 (6.7) |
| Inhaled corticosteroids | 5 (33.3) |
| Antihistamines | 2 (13.3) |